Short Interest in Ralliant Corporation (NYSE:RAL) Decreases By 14.4%

Ralliant Corporation (NYSE:RAL) was the target of a large drop in short interest in January. As of January 15th, there was short interest totaling 2,361,505 shares, a drop of 14.4% from the December 31st total of 2,758,217 shares. Based on an average daily volume of 1,039,281 shares, the days-to-cover ratio is currently 2.3 days. Approximately 2.1% of the shares of the stock are sold short. Approximately 2.1% of the shares of the stock are sold short. Based on an average daily volume of 1,039,281 shares, the days-to-cover ratio is currently 2.3 days.

Analysts Set New Price Targets

RAL has been the subject of a number of analyst reports. Oppenheimer upped their price target on Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Barclays upped their target price on Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Citigroup upgraded Ralliant from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $53.00 to $61.00 in a report on Monday, December 8th. Truist Financial assumed coverage on shares of Ralliant in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $58.00.

Institutional Trading of Ralliant

Institutional investors have recently added to or reduced their stakes in the stock. Ethic Inc. purchased a new stake in Ralliant in the fourth quarter valued at approximately $767,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Ralliant in the fourth quarter valued at $215,000. Danske Bank A S purchased a new stake in shares of Ralliant in the 4th quarter valued at $25,000. Oppenheimer & Co. Inc. acquired a new position in Ralliant during the 4th quarter worth about $221,000. Finally, Oppenheimer Asset Management Inc. lifted its stake in Ralliant by 18.4% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 10,725 shares of the company’s stock worth $546,000 after acquiring an additional 1,664 shares in the last quarter.

Ralliant Stock Performance

NYSE RAL opened at $54.62 on Wednesday. The stock has a fifty day simple moving average of $51.78 and a 200-day simple moving average of $46.76. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39. The stock has a market cap of $6.16 billion and a PE ratio of 43.01. Ralliant has a twelve month low of $40.70 and a twelve month high of $55.25.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.02. The company had revenue of $529.10 million during the quarter, compared to analysts’ expectations of $519.14 million.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s payout ratio is 15.75%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.